Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways

References

• Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12:646–653. doi:10.1038/nrendo.2016.110.
   PubMed Web of Science ®Google Scholar
• Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058–1069. doi:10.1016/S0140-6736(13)60109-9.
   PubMed Web of Science ®Google Scholar
• Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem. 1994;269:25277–25282.
   PubMed Web of Science ®Google Scholar
• Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267:226–244. doi:10.1016/j.canlet.2008.04.050.
   PubMed Web of Science ®Google Scholar
• Cui D, Zhao Y, Xu J. Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of beta-catenin pathway. Biochimie. 2018. doi:10.1016/j.biochi.2018.02.009.
   Web of Science ®Google Scholar
• Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA. CXCL5 promotes prostate cancer progression. Neoplasia. 2008;10:244–254.
   PubMed Web of Science ®Google Scholar
• Hsu YL, Hou MF, Kuo PL, Huang YF, Tsai EM. Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway. Oncogene. 2013;32:4436–4447. doi:10.1038/onc.2012.444.
   PubMed Web of Science ®Google Scholar
• Peluso I, Yarla NS, Ambra R, Pastore G, Perry G. MAPK signalling pathway in cancers: olive products as cancer preventive and therapeutic agents. Semin Cancer Biol. 2017. doi:10.1016/j.semcancer.2017.09.002.
   PubMedGoogle Scholar
• Dhanasekaran DN, Reddy EP. JNK-signaling: A multiplexing hub in programmed cell death. Genes Cancer. 2017;8:682–694. doi:10.18632/genesandcancer.155.
   PubMedGoogle Scholar
• Wang X, Chao L, Zhen J, Chen L, Ma G, Li X. Phosphorylated c-Jun NH2-terminal kinase is overexpressed in human papillary thyroid carcinomas and associates with lymph node metastasis. Cancer Lett. 2010;293:175–180. doi:10.1016/j.canlet.2010.01.007.
   PubMed Web of Science ®Google Scholar
• Grassi ES, Vezzoli V, Negri I, Labadi A, Fugazzola L, Vitale G, Persani L. SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget. 2015;6:36383–36399. doi:10.18632/oncotarget.5799.
   PubMedGoogle Scholar
• Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM, Xiang J, Lu Z-W, Zhu Y-X, Li D-S, et al. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer. Oncotarget. 2017;8:238–247. doi:10.18632/oncotarget.10825.
   PubMedGoogle Scholar
• Balamayooran G, Batra S, Cai S, Mei J, Worthen GS, Penn AL, Jeyaseelan S. Role of CXCL5 in leukocyte recruitment to the lungs during secondhand smoke exposure. Am J Respir Cell Mol Biol. 2012;47:104–111. doi:10.1165/rcmb.2011-0260OC.
   PubMed Web of Science ®Google Scholar
• Brzezinski J, Migodzinski A, Gosek A, Tazbir J, Dedecjus M. Cyclin E expression in papillary thyroid carcinoma: relation to staging. Int J Cancer. 2004;109:102–105. doi:10.1002/ijc.11673.
   PubMed Web of Science ®Google Scholar
• Lamba Saini M, Bouzin C, Weynand B, Marbaix E. An appraisal of proliferation and apoptotic markers in papillary thyroid carcinoma: an automated analysis. PLoS One. 2016;11:e0148656. doi:10.1371/journal.pone.0148656.
   PubMed Web of Science ®Google Scholar
• Kim NY, Kim JH, Pyo JS, Jin Cho W. Clinicopathological significance of loss of p27kip1 expression in papillary thyroid carcinoma. Int J Biol Markers. 2017;32:e255–e9. doi:10.5301/jbm.5000239.
   PubMed Web of Science ®Google Scholar
• Kuo PL, Chen YH, Chen TC, Shen KH, Hsu YL. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol. 2011;226:1224–1231. doi:10.1002/jcp.22445.
   PubMed Web of Science ®Google Scholar
• Murphy CG, Dickler MN. The role of CDK4/6 inhibition in breast cancer. Oncologist. 2015;20:483–490. doi:10.1634/theoncologist.2014-0443.
   PubMed Web of Science ®Google Scholar
• Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014;5:6512–6525. doi:10.18632/oncotarget.2270.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Lee WK, Kang CW, Ku CR, Cho YH, Lee EJ. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Lett. 2018;417:131–140. doi:10.1016/j.canlet.2017.12.037.
   PubMed Web of Science ®Google Scholar
• Lopes-Ventura S, Pojo M, Matias AT, Moura MM, Marques IJ, Leite V, Cavaco BM. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines. J Endocrinol Invest. 2018. doi:10.1007/s40618-018-0947-4.
   PubMedGoogle Scholar
• Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang X-W, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56:2242–2254. doi:10.1002/hep.25907.
   PubMed Web of Science ®Google Scholar
• Speetjens FM, Kuppen PJ, Sandel MH, Menon AG, Burg D, van de Velde CJ, Tollenaar RAEM, de Bont HJGM, Nagelkerke JF. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res. 2008;14:2276–2284. doi:10.1158/1078-0432.CCR-07-4045.
   PubMed Web of Science ®Google Scholar
• Vasilevskaya I, O’Dwyer PJ. Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat: Rev Commentaries Antimicrobial Anticancer Chemo. 2003;6:147–156.
   Google Scholar
• Glassmann A, Winter J, Kraus D, Veit N, Probstmeier R. Pharmacological suppression of the Ras/MAPK pathway in thyroid carcinoma cells can provoke opposite effects on cell migration and proliferation: the appearance of yin-yang effects and the need of combinatorial treatments. Int J Oncol. 2014;45:2587–2595. doi:10.3892/ijo.2014.2668.
   PubMed Web of Science ®Google Scholar
• Yu W, Imoto I, Inoue J, Onda M, Emi M, Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene. 2007;26:1178–1187. doi:10.1038/sj.onc.1209899.
   PubMed Web of Science ®Google Scholar
• Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S. Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis. Cancer Lett. 2017;395:1–10. doi:10.1016/j.canlet.2017.02.028.
   PubMed Web of Science ®Google Scholar
• Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene. 2011;30:3153–3162. doi:10.1038/onc.2011.44.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C, Liu D, Zheng M, Sun J, Feng H, et al. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3beta/beta-catenin pathways. Mol Cancer. 2017;16:70. doi:10.1186/s12943-017-0629-4.
   PubMed Web of Science ®Google Scholar
• Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002;4:556–564. doi:10.1038/ncb822.
   PubMed Web of Science ®Google Scholar
• Feniger-Barish R, Belkin D, Zaslaver A, Gal S, Dori M, Ran M, Ben-Baruch A. GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR(+)-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling. Blood. 2000;95:1551–1559.
   PubMed Web of Science ®Google Scholar
• Fan GH, Yang W, Wang XJ, Qian Q, Richmond A. Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization. Biochemistry. 2001;40:791–800.
   PubMed Web of Science ®Google Scholar
• Qiu WZ, Zhang HB, Xia WX, Ke LR, Yang J, Yu YH, Liang H, Huang X-J, Liu G-Y, Li W-Z, et al. The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3beta/snail signalling. J Exp Clin Cancer Res. 2018;37:85. doi:10.1186/s13046-018-0722-6.
   PubMed Web of Science ®Google Scholar
• Auer PL, Teumer A, Schick U, O’Shaughnessy A, Lo KS, Chami N, Carlson C, de Denus S, Dubé M-P, Haessler J, et al. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. Nat Genet. 2014;46:629–634. doi:10.1038/ng.2962.
   PubMed Web of Science ®Google Scholar
• Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, Bradley ME. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol. 2010;159:1429–1439. doi:10.1111/j.1476-5381.2009.00623.x.
   PubMed Web of Science ®Google Scholar
• Kato H, Tsuchiya N, Tokunaga K. Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3. Genes Immun. 2000;1:330–337. doi:10.1038/sj.gene.6363682.
   PubMed Web of Science ®Google Scholar
• Leclair HM, Dubois SM, Azzi S, Dwyer J, Bidere N, Gavard J. Control of CXCR2 activity through its ubiquitination on K327 residue. BMC Cell Biol. 2014;15:38. doi:10.1186/s12860-014-0038-0.
   PubMed Web of Science ®Google Scholar